Skip to main content
Log in

Estimation, Power and Sample Size Calculations for Stochastic Cost and Effectiveness Analysis

  • Practical Application
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Various methods have been proposed to address uncertainty in economic evaluations of healthcare programmes. One approach suggested in the literature is to estimate separate confidence intervals for the incremental costs and effects of a new health programme in comparison with an existing programme. These intervals are then combined to generate a rectangular confidence region in the cost-effectiveness plane that implicitly defines a corresponding confidence interval for the incremental cost-effectiveness ratio (ICER). The same approach has been used to calculate sample sizes and study power. This application of the rectangle method is consistent with the adoption of ICERs and a threshold as a decision rule, this being the most commonly used approach in empirical applications of cost-effectiveness analysis, as well as the one recommended by agencies that assess medical technology around the world.

In this paper, we first outline the rectangle method, and then propose a modification that recognises that separate inferences are being drawn on the cost and effectiveness domains, and that corrects for multiple statistical comparisons. The confidence rectangle is otherwise too small, the corresponding confidence interval for the ICER is too narrow and sample sizes are under-estimated. Our modification corrects these problems.

A further difficulty is that the placement of the confidence rectangle around the null value is somewhat arbitrary, and does not correspond to a unique value of ICERs. As a result, different values of sample size and power for the estimation of ICERs can be obtained, depending on the null values of the cost and effectiveness. We conclude that it is important to clearly identify the analytic goal in terms of estimating differential costs, differential effects or a combination of the two using the ICER index. These ideas are illustrated using numerical examples.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Table I
Table II
Fig. 3
Table III
Fig. 4
Table IV

Similar content being viewed by others

References

  1. Gardiner J, Huebner M, Jeton J, et al. Power and sample size assessments for test hypotheses on cost-effectiveness ratios. Health Econ 2000; 9: 227–234

    Article  PubMed  CAS  Google Scholar 

  2. Backhouse ME. Use of randomized controlled trials for producing cost-effectiveness evidence. Pharmacoeconomics 2002; 20: 1061–1077

    Article  PubMed  Google Scholar 

  3. Briggs AH, Gray AM. Power and sample size calculations for stochastic cost-effectiveness analysis. Med Dec Making 1998; 18 Suppl.: S81–S92

    Article  CAS  Google Scholar 

  4. Willan A, O’Brien B. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ 1999; 8: 203–211

    Article  PubMed  CAS  Google Scholar 

  5. Fieller EC. Some problems in interval estimation. J Royal Statist Soc, Series B, 1954; 16: 175–183

    Google Scholar 

  6. Laska E, Meisner M, Siegel C. Power and sample size in cost-effectiveness analysis. Med Dec Making 1999; 19: 339–343

    Article  CAS  Google Scholar 

  7. Al M, Van Hout B, Michel B, et al. Sample size calculations in economic evaluations. Health Econ 1998; 7: 327–335

    Article  PubMed  CAS  Google Scholar 

  8. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost effectiveness analysis. Health Econ 2002; 11: 415–430

    Article  PubMed  Google Scholar 

  9. Briggs AH, O’Brien BJ, Blackhause G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Am Rev Public Health 2002; 23: 377–401

    Article  Google Scholar 

  10. Birch S, Gafni A. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. Health Econ 2002; 11: 185–191

    Article  PubMed  Google Scholar 

  11. Gafni A, Birch S. Inclusion of drugs in provincial drug benefit programs: should’ reasonable decisions’ lead to uncontrolled growth in expenditures? Can Med Assoc J 2003; 168: 849–851

    Google Scholar 

  12. Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluations of health care programs. Health Econ 2002; 11: 23–31

    Article  PubMed  CAS  Google Scholar 

  13. O’Brien B, Gertsen K, Willan A, et al. Is there a kink in consumers’ threshold value for cost-effectiveness in health care? Health Econ 2002; 11: 175–180

    Article  PubMed  Google Scholar 

  14. Cook RJ, Dunnett CW. Multiple comparisons. In: Armitage P, Colton T, editors. Encyclopedia of biostatistics. New York: Wiley, 1999: 2736–2746

    Google Scholar 

  15. Sidak Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc 1967; 62: 626–633

    Google Scholar 

  16. Polsky D, Glick HA, Willke R, et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997; 6: 243–252

    Article  PubMed  CAS  Google Scholar 

  17. Birch S, Gafni A. Cost effectiveness/utility analysis: do current decision rules lead us to where we want to be? J Health Econ 1992; 11: 279–296

    Article  PubMed  CAS  Google Scholar 

  18. Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein’s (mis)application of economics to real world problems. J Health Econ 1993; 12: 469–476

    Article  PubMed  CAS  Google Scholar 

  19. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18 (3): 341–364

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No funding was used for the preparation of this manuscript. The authors declare they have no conflicts of interest directly relevant to the contents of this paper.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. D. Walter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walter, S.D., Gafni, A. & Birch, S. Estimation, Power and Sample Size Calculations for Stochastic Cost and Effectiveness Analysis. Pharmacoeconomics 25, 455–466 (2007). https://doi.org/10.2165/00019053-200725060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200725060-00002

Keywords

Navigation